Abstract Session 9

Co-Chair(s)

• 

  Javier de la Rubia, Prof. Dr. (he/him/his)

  Head of Department
  Hematology Department, University Hospital La Fe
  Valencia, Comunidad Valenciana, Spain
• 

  Cyrille Touzeau, MD, PhD

  Hematologist
  CHU Nantes
  Nantes, France

Presentations:

• 10:00 AM – 10:12 AM East Coast USA Time

  OA – 13: Belantamab mafodotin, pomalidomide, and dexamethasone vs pomalidomide, bortezomib, and dexamethasone in patients with relapsed/refractory multiple myeloma: patient-reported outcomes from DREAMM-8
  

  Speaker: Meletios A. Dimopoulos, MD – National and Kapodistrian University of Athens
• 10:12 AM – 10:24 AM East Coast USA Time

  OA – 15: Maintenance Therapy Cessation for Multiple Myeloma Patients with Three-Year Sustained MRD Negative Remissions
  

  Speaker: Neha Korde, MD – Memorial Sloan Kettering Cancer Center
• 10:24 AM – 10:36 AM East Coast USA Time

  OA – 43: Interim Results of a Phase 2 Trial of Isatuximab-Lenalidomide for Patients with High-Risk Smoldering Multiple Myeloma
  

  Speaker: Sheeba Thomas, MD (she/her/hers) – MD Anderson Cancer Center
• 10:36 AM – 10:48 AM East Coast USA Time

  OA – 44: Frontline Systemic Treatment Outcomes in POEMS Syndrome – Analysis from the UCLH POEMS Centre Registry Spanning 25 Years
  

  Speaker: Oliver M. Tomkins, MRCP FRCPath – University College London Hospitals NHS Foundation Trust
• 10:48 AM – 11:00 AM East Coast USA Time

  OA – 59: Proteasome inhibitor-augmented salvage autologous stem cell transplantation for first relapse management in Relapsed Multiple Myeloma.
  

  Speaker: Christopher Parrish, PhD (he/him/his) – Leeds Teaching Hospitals NHS Trust